Use of cetuximab in combination with pulsed reduced dose-rate radiotherapy in a patient with recurrence of nasopharyngeal carcinoma in the neck

Li,Guang-Hui; Zhu,Bo; Yang,Fan; Ma,Chuan-Kun; Yang,Ding-Qiang

doi:10.3892/etm.2012.506

Use of cetuximab in combination with pulsed reduced dose-rate radiotherapy in a patient with recurrence of nasopharyngeal carcinoma in the neck

Authors:
- Guang-Hui Li
- Bo Zhu
- Fan Yang
- Chuan-Kun Ma
- Ding-Qiang Yang
View Affiliations

Affiliations: Institute for Cancer Research in People's Liberation Army, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, P.R. China
Published online on: March 5, 2012 https://doi.org/10.3892/etm.2012.506
Pages: 869-872

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Reirradiation is a major therapeutic modality for patients with locally recurrent head and neck carcinoma. Due to normal tissue tolerances, reirradiation using conventional techniques has a narrow therapeutic ratio in the regional recurrence of nasopharyngeal carcinoma (NPC). Pulsed reduced dose‑rate radiotherapy (PRDR), which delivers a series of 0.2 Gy pulses separated by 3 min intervals, is a new reirradiation technique. Head and neck carcinoma cells have high levels of epidermal growth factor receptor expression and cetuximab shows a clear benefit to locally advanced head and neck carcinoma. We report a 56-year-old male with a recurrent lesion of NPC in the neck following initial radical radiochemotherapy. The patient was retreated with PRDR and concurrent cetuximab. The total dose of PRDR was 70 Gy, using 35 daily fractions of 2.0 Gy. The recurrent lesion of this patient had a complete response with no apparent radiation‑induced normal tissue complications. This is the first study concerning PRDR combined with cetuximab for the treatment of recurrent head and neck carcinoma following radiotherapy. The outcome of this patient reveals that treatment with PRDR and concurrent cetuximab is a promising therapeutic option for patients with recurrent head and neck carcinoma following radiotherapy.

View Figures

View References

1.	Shen C, Gao Y, Xu T, et al: Carcinoma of the nasopharynx in young patients: a single institution experience. Clin Oncol (R Coll Radiol). 21:617–622. 2009. View Article : Google Scholar : PubMed/NCBI
2.	Yi JL, Gao L, Huang XD, et al: Nasopharyngeal carcinoma treated by radical radiotherapy alone: ten-year experience of a single institution. Int J Radiat Oncol Biol Phys. 65:161–168. 2006.PubMed/NCBI
3.	Sher DJ, Haddad RI, Norris CM, et al: Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer. 116:4761–4768. 2010. View Article : Google Scholar : PubMed/NCBI
4.	Adkison JB, Tomé W, Seo S, et al: Reirradiation of large-volume recurrent glioma with pulsed reduced-dose-rate radiotherapy. Int J Radiat Oncol Biol Phys. 79:835–841. 2011.PubMed/NCBI
5.	Richards GM, Tomé WA, Robins HI, et al: Pulsed reduced dose-rate radiotherapy: a novel locoregional retreatment strategy for breast cancer recurrence in the previously irradiated chest wall, axilla, or supraclavicular region. Breast Cancer Res Treat. 114:307–313. 2009. View Article : Google Scholar
6.	Chung CH, Ely K, McGavran L, et al: Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol. 24:4170–4176. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Zimmermann M, Zouhair A, Azria D and Ozsahin M: The epidermal growth factor recepter (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol. 1:11–16. 2006. View Article : Google Scholar : PubMed/NCBI
8.	Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
9.	Sharafinski ME, Ferris RL, Ferrone S and Grandis JR: Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck. 32:1412–1421. 2010. View Article : Google Scholar : PubMed/NCBI
10.	Greene FL, wPage DL, Fleming ID, Fritz A, Balch CM, Haller DG and Morros M: AJCC Cancer Staging Manual. 6th ed. Springer-Verlag; New York: 2002, View Article : Google Scholar
11.	Mendelsohn J and Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 21:2787–2799. 2003. View Article : Google Scholar : PubMed/NCBI
12.	Harney J, Short SC, Shah N, et al: Low dose hyperradiosensitivity in metastatic tumors. Int J Radiat Oncol Biol Phys. 59:1190–1195. 2004. View Article : Google Scholar : PubMed/NCBI
13.	Lin PS and Wu A: Not all 2 Gray radiation prescriptions are equivalent: cytotoxic effect depends on delivery sequences of partial fractionated doses. Int J Radiat Oncol Biol Phys. 63:536–544. 2005. View Article : Google Scholar : PubMed/NCBI
14.	Specenier P and Vermorken JB: Cetuximab in the treatment of squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther. 11:511–524. 2011. View Article : Google Scholar : PubMed/NCBI
15.	Walsh L, Gillham C, Dunne M, et al: Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiother Oncol. 98:38–41. 2011. View Article : Google Scholar : PubMed/NCBI
16.	Pryor DI, Porceddu SV, Burmeister BH, et al: Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol. 90:172–176. 2009. View Article : Google Scholar : PubMed/NCBI
17.	Bossi P, Liberatoscioli C, Bergamini C, et al: Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. Ann Oncol. 18:601–602. 2007. View Article : Google Scholar
18.	Kanakamedala MR, Packianathan S and Vijayakumar S: Lack of cetuximab induced skin toxicity in a previously irradiated field: case report and review of the literature. Radial Oncol. 5:38–41. 2010. View Article : Google Scholar : PubMed/NCBI